Aortic valve regurgitation following percutaneous closure of patent ductus arteriosus

Catheter Cardiovasc Interv. 2011 Feb 15;77(3):416-9. doi: 10.1002/ccd.22529.

Abstract

Objectives: To determine the incidence and outcome of aortic valve regurgitation (AR) following the percutaneous closure of patent ductus arteriosus (PDA).

Background: Aortic valve regurgitation is an overlooked consequence of percutaneous PDA closure.

Methods: Between December 2000 and May 2009, 51 children underwent percutaneous closure of PDA using Amplatzer Duct Occluders. Their median age at the time of the procedure was 2.6 years (range: 0.6-18.0 years), and median weight was 14.0 kg (range: 7.6-75.0 kg). Follow-up echocardiograms were performed a day after the procedure and at 1, 3, 12 months, and yearly thereafter.

Results: A day after the procedure, AR was detected for the first time in 13 of 48 patients (27.0%). A group of patients with newly developed AR was significantly different from a group of patients with competent aortic valves with respect to their age, weight, and minimal PDA diameter indexed to the body weight. The follow-up period ranged from 0.2 to 8.5 years (median 3.3 years) and at the latest follow-up evaluation, AR persisted in a single patient (2.0%) 6 years after the procedure.

Conclusions: The aortic valve regurgitation following percutaneous PDA closure is trivial to mild and transient. It develops in approximately a quarter of children after percutaneous closure of PDA with a minimal diameter≥1.5 mm and is more likely to develop in infants and small children having significant left-to-right shunts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aortic Valve Insufficiency / diagnostic imaging
  • Aortic Valve Insufficiency / epidemiology
  • Aortic Valve Insufficiency / etiology*
  • Cardiac Catheterization / adverse effects*
  • Cardiac Catheterization / instrumentation
  • Child
  • Child, Preschool
  • Ductus Arteriosus, Patent / diagnostic imaging
  • Ductus Arteriosus, Patent / therapy*
  • Echocardiography, Doppler, Color
  • Humans
  • Incidence
  • Infant
  • Kaplan-Meier Estimate
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Severity of Illness Index
  • Slovenia
  • Time Factors
  • Treatment Outcome